BR112017010832A2 - composições de aminoácido para o tratamento de sintomas de doença - Google Patents

composições de aminoácido para o tratamento de sintomas de doença

Info

Publication number
BR112017010832A2
BR112017010832A2 BR112017010832A BR112017010832A BR112017010832A2 BR 112017010832 A2 BR112017010832 A2 BR 112017010832A2 BR 112017010832 A BR112017010832 A BR 112017010832A BR 112017010832 A BR112017010832 A BR 112017010832A BR 112017010832 A2 BR112017010832 A2 BR 112017010832A2
Authority
BR
Brazil
Prior art keywords
amino acid
disease symptoms
acid compositions
treating disease
group
Prior art date
Application number
BR112017010832A
Other languages
English (en)
Inventor
B Dennison Daniel
Vidyasagar Sadasivan
J Gatto Stephen
Original Assignee
Entrinsic Health Solutions Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Entrinsic Health Solutions Llc filed Critical Entrinsic Health Solutions Llc
Publication of BR112017010832A2 publication Critical patent/BR112017010832A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • AIDS & HIV (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

a presente invenção fornece composições terapêuticas e usos das mesmas para o tratamento ou melhora de sintomas de uma doença selecionada a partir do grupo que consiste em: infecção por vírus ebola, infecção por hiv, ataxia, enteropatia ambiental, câncer, ressaca, doença inflamatória e diarreia epidêmica suína. em modalidades preferenciais, a composição inclui uma combinação de um ou mais aminoácidos selecionados a partir do grupo que compreende lisina, ácido aspártico, glicina, isoleucina, treonina, tirosina, valina, triptofano, asparagina e/ou serina.
BR112017010832A 2014-11-24 2015-11-19 composições de aminoácido para o tratamento de sintomas de doença BR112017010832A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462083698P 2014-11-24 2014-11-24
US201562138051P 2015-03-25 2015-03-25
PCT/US2015/061462 WO2016085735A1 (en) 2014-11-24 2015-11-19 Amino acid compositions for the treatment of symptoms of disease

Publications (1)

Publication Number Publication Date
BR112017010832A2 true BR112017010832A2 (pt) 2017-12-26

Family

ID=56074902

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017010832A BR112017010832A2 (pt) 2014-11-24 2015-11-19 composições de aminoácido para o tratamento de sintomas de doença

Country Status (8)

Country Link
US (4) US20170326088A1 (pt)
EP (3) EP3223809A4 (pt)
JP (1) JP2017535591A (pt)
CN (1) CN107106527B (pt)
BR (1) BR112017010832A2 (pt)
CA (1) CA2968831A1 (pt)
MX (1) MX2017006748A (pt)
WO (1) WO2016085735A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7267546B2 (ja) * 2016-10-04 2023-05-02 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド アミノ酸組成物及びその使用
JP2019043861A (ja) * 2017-08-30 2019-03-22 アサヒグループホールディングス株式会社 乳酸／ピルビン酸比の改善用組成物
WO2019070753A1 (en) * 2017-10-02 2019-04-11 University Of Florida Research Foundation, Incorporated AMINO ACID COMPOSITIONS AND METHODS FOR TREATING DIARRHEA
CN112188891A (zh) * 2018-04-04 2021-01-05 佛罗里达大学研究基金会公司 用于治疗皮肤的组合物
IT201800005599A1 (it) * 2018-05-22 2019-11-22 Lente a contatto morbida
CN108434304A (zh) * 2018-05-23 2018-08-24 北京雄九医学研究院 防癌抗癌中药的制备方法
JP2023533617A (ja) * 2020-07-02 2023-08-03 ユニバーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイティド 水分補給を促進するための製剤およびその使用方法
US11878073B1 (en) 2022-09-20 2024-01-23 Entrinsic, LLC Generation of hydration-targeted formulations and methods of use therein

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994016757A2 (en) 1991-03-05 1994-08-04 Miris Medical Corporation Apparatus for providing a timed release of an amount of aerosol medication
ATE359842T1 (de) 1991-07-02 2007-05-15 Nektar Therapeutics Abgabevorrichtung für nebelförmige medikamente
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US5558085A (en) 1993-01-29 1996-09-24 Aradigm Corporation Intrapulmonary delivery of peptide drugs
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
KR19980702436A (ko) 1995-02-23 1998-07-15 하인쯔 쉬나이더, 미첼 오르진거 아미노산 조성물 및 임상용 영양물내에 이의 사용 방법
AU6014098A (en) 1996-12-31 1998-07-31 Inhale Therapeutic Systems Aerosolized hydrophobic drug
EP1137805A4 (en) 1998-11-13 2003-03-26 Los Angeles Childrens Hospital METHODS FOR FACILITATING VASCULAR GROWTH
AU2001223942A1 (en) 2000-01-14 2001-07-24 Olafur Halldorsson Marine lipid composition for feeding aquatic organisms
GB0009056D0 (en) 2000-04-12 2000-05-31 Nestle Sa Composition comprising free amino acids
US7063865B2 (en) * 2002-05-10 2006-06-20 Jeremy Park Jones Composition and method for substantially reducing the deleterious effects of alcohol on the body
US20040087490A1 (en) * 2002-09-20 2004-05-06 Troup John P. Nutritional compositions
US20070010459A1 (en) 2005-01-14 2007-01-11 Ying Liu Application of asiatic acid and its derivatives to treat pulmonary fibrosis
EP1864692A1 (en) 2006-06-07 2007-12-12 Biotempt B.V. Use of peptides for the control of radiation injury
JP2011511620A (ja) * 2007-08-03 2011-04-14 アミノテック アーエス アミノ酸及びペプチド製品
IT1396935B1 (it) 2009-11-26 2012-12-20 Solartium Entpr Ltd Uso di una combinazione per il trattamento delle mucositi indotte da radiazioni o da chemioterapici
IT1397861B1 (it) * 2010-01-27 2013-02-04 Ambrosialab Srl Metodo e composizioni per l'applicazione di aminoacidi sulla pelle mediante un mezzo anidro
GB201012539D0 (en) 2010-07-27 2010-09-08 Savantium Ltd Nutritional compositions
WO2012040707A2 (en) 2010-09-24 2012-03-29 University Of Florida Research Foundation, Inc. Materials and methods for improving gastrointestinal function
CA2831341A1 (en) * 2011-04-12 2012-10-18 Nestec S.A. Nutritional compositions including branched chain fatty acids for wound healing
CA2855854C (en) * 2011-11-21 2020-03-31 The Institute For Ethnomedicine L-serine compositions, methods and uses for treating neurodegenerative diseases and disorders
EA034014B1 (ru) * 2012-02-08 2019-12-19 Юниверсити Оф Флорида Рисёч Фаундейшн, Инк. Способ лечения субъекта с диареей, вызванной ротавирусом
US9987306B2 (en) * 2012-10-15 2018-06-05 University Of Florida Research Foundation, Inc. Materials and methods for prevention and treatment of diarrhea and inflammation in the gastrointestinal tract

Also Published As

Publication number Publication date
CN107106527B (zh) 2020-11-24
US10758506B2 (en) 2020-09-01
EP3223809A4 (en) 2018-08-15
WO2016085735A1 (en) 2016-06-02
EP3459540A1 (en) 2019-03-27
US20200368194A1 (en) 2020-11-26
US20180289648A1 (en) 2018-10-11
JP2017535591A (ja) 2017-11-30
US20220347143A1 (en) 2022-11-03
US11357747B2 (en) 2022-06-14
EP3223809A1 (en) 2017-10-04
US20170326088A1 (en) 2017-11-16
CN107106527A (zh) 2017-08-29
CA2968831A1 (en) 2016-06-02
EP3616689A1 (en) 2020-03-04
MX2017006748A (es) 2017-08-28

Similar Documents

Publication Publication Date Title
BR112017010832A2 (pt) composições de aminoácido para o tratamento de sintomas de doença
CO2018000104A2 (es) Moléculas de anticuerpo que se unen a cd22
BR112012018947B1 (pt) anticorpo anti-caprin-1 monoclonal, composição farmacêutica, combinação farmacêutica e usos de uma composição farmacêutica, de um anticorpo e de uma combinação farmacêutica
BR112015019066A2 (pt) Anticorpos humanos para proteína f do vírus respiratório sincicial e métodos de uso dos mesmos
BR112017010893A2 (pt) análogos de ácidos biliares como agonistas de fxr/tgr5 e métodos de uso dos mesmos
BR112012018951B8 (pt) anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica
BR112017023161A2 (pt) composições de ácido obeticólico e métodos de uso
BR112017008165A2 (pt) anticorpos de domínio único direcionados contra antígenos intracelulares
BR112014021104A2 (pt) métodos e composições para o tratamento da doença de huntington
CL2018000107A1 (es) Moléculas de anticuerpo que se unen a cd79
CL2017002082A1 (es) Nuevas proteínas especificas para pioverdina y pioquelina
BR112015010059A2 (pt) terapia adjuvante com inibidor da quinase da família tec
BR112014021102A2 (pt) Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo
AR090465A1 (es) Formas solidas de un profarmaco de nucleotidos de tiofosforamidato
BR112017002761A2 (pt) composições anti-metanogênicas e usos das mesmas
BR112014026740A2 (pt) anticorpo, composição, métodos para tratar um mamífero e para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo
CL2017002729A1 (es) Proteína de unión a rgma y su uso
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
BR112015013349A2 (pt) trieptanoína para o tratamento de deficiência de transportador de glicose 1
BR112014024751A2 (pt) antígenos de clostridium difficile
BR112016015701A2 (pt) Dendrímero de peptídeo, método de esterilização do mesmo, composição, composição farmacêutica, método de polimerização de fibrinogênio, kit para formação de um hidrogel e hidrogel
BR112017000312A2 (pt) sistema de tratamento da saúde bucal para a aplicação de fosfato de cálcio amorfo, uso de um ou mais aminoácidos básicos, composição, e uso de um ou mais aminoácidos em um sistema de tratamento da saúde bucal
BR112016001919A2 (pt) composição cosmética e processo de tratamento cosmético
EA201790558A1 (ru) Композиция с пониженной иммуногенностью
BR112019002458A2 (pt) composições e métodos para tratar câncer com depleção de arginina e agentes imuno-oncológicos

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority
B151 Others concerning applications: resolution cancelled [chapter 15.31 patent gazette]
B25D Requested change of name of applicant approved

Owner name: ENTRINSIC HEALTH SOLUTIONS, INC. (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements